Psoriatic Arthritis Therapeutics Market - Snapshot

The global psoriatic arthritis therapeutics market is expanding at a rapid pace due to high prevalence and increase in incidence rate of psoriatic arthritis and new product development and commercialization across the globe. In terms of revenue, the global market was valued at US$ 6,011.7 Mn in 2017 and is projected to reach US$ 17,118.7 Mn by 2026, expanding at a CAGR of 11.4% from 2018 to 2026. The global psoriatic arthritis therapeutics market is also driven by rise in adoption of biologics for the treatment of moderate to severe psoriatic arthritis and large patient population with unmet medical needs across the globe. 

psoriatic arthritis therapeutics market

Psoriatic arthritis is a chronic autoimmune inflammatory disorder that causes inflammation, swelling, and stiffness at any joint of the body. Psoriatic arthritis is a progressive form of psoriasis, characterized by the itchy, scaly red patches on the skin. It is estimated that more than 125 million people around the world are affected with psoriasis, and 30% of the psoriasis population tend to develop psoriatic arthritis. The common symptoms of psoriatic arthritis include swollen fingers, toes, and tender joints, stiffness, lower back pain, and pitted nails. Psoriatic arthritis is a non-curable disease and treatments are aimed at relieving the symptoms of the condition. Various over-the-counter and prescription drugs are available and several more are in different stages of clinical trials in order to treat the symptoms of psoriatic arthritis. 

The global psoriatic arthritis therapeutics market is driven by intensive research to provide treatments and/or relieve the symptoms of the condition. There is a large patient population suffering from moderate to severe psoriatic arthritis with unmet medical needs, and the number is increasing across the globe. Leading pharmaceutical companies are striving to address these unmet medical needs through new product development. Large number of both small molecules and biologic products are under different phases of clinical trials for the treatment of psoriatic arthritis. Companies have made significant investments in clinical R&D and have also established strategic partnerships and collaborations to accelerate new product development. Interleukin inhibitors drugs have proven to be effective and well-tolerated treatment for psoriatic arthritis and recently, around three different interleukin inhibitors have been approved and commercialized in the U.S. and Europe. Numerous different drugs candidates are under interleukin inhibitors that are in phase III clinical trials for psoriatic arthritis treatment, which are likely to commercialize in first half of the forecast period. High prevalence and rise in incidence rates of psoriatic arthritis with significant unmet medical needs are projected to propel the global psoriatic arthritis therapeutics market during the forecast period. 

The global psoriatic arthritis therapeutics market has been segmented based on drug class, route of administration, distribution channel, and region. In terms of drug class, the global market has been classified into TNF inhibitors, interleukin inhibitors, PDE4 inhibitors, and others. The TNF inhibitors segment dominated the global market in 2017. Large patient population with psoriasis, long-term management of moderate to severe psoriatic arthritis, and high cost of TNF inhibitors contributed to the high market share held by the segment in 2017. The interleukin inhibitors segment is estimated gain market share significantly by the end of 2026. The PDE4 inhibitors segment is estimated to expand at a rapid pace during the forecast period, owing to high clinical efficacy, increased demand, and low cost of drugs. 

In terms of route of administration, the global psoriatic arthritis therapeutics market has been segmented into oral, parenteral, and topical. The parenteral segment accounted for a prominent share of the global market in 2017. It is estimated to expand at a notable growth rate during the forecast period. The large share held by the parenteral segment is attributed to the high cost of biologic drugs, which are administered through intravenous and subcutaneous routes, large number of biologic and biosimilar drugs under clinical pipeline trials, and estimated increase in adoption of biosimilar drugs during the forecast period. 

Based on distribution channel, the global psoriatic arthritis therapeutics market has been divided into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment dominated the global market in 2017. It is projected to gain market share by the end of 2026. Long-term management of severe psoriatic arthritis, increase in rate of hospitalization, and availability of high cost biologic drugs are attributed to the large share of the market held by the segment in 2017. The hospital pharmacies segment is anticipated to expand at a significant growth rate during the forecast period. 

In terms of region, the global psoriatic arthritis therapeutics market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is expected to account for more than of 50% share of the global market by 2026. High prevalence of psoriatic arthritis, increase in adoption of biologic drugs for the treatment of moderate to severe psoriatic arthritis, and anticipated new product approvals are likely to fuel the psoriatic arthritis therapeutics market in North America. The market in Asia Pacific is projected to expand at a prominent CAGR during the forecast period. Increase in awareness about psoriatic arthritis, rapidly changing health care infrastructure, rise in access to psoriatic arthritis treatments in developing countries such as China and India, well-established pharmaceutical market in Japan, and surge in adoption of biologic drugs in Australia and New Zealand are anticipated to fuel the psoriatic arthritis therapeutics market in Asia Pacific during the forecast period. 

Majority of biopharmaceutical companies have made significant investments in the clinical research and development of Psoriatic Arthritis treatment products. Mergers and acquisitions among leading players has been a key trend in the global market in the last few years. Key players operating in the global psoriatic arthritis therapeutics market include AbbVie, Inc., Janssen Biotech, Inc., Novartis AG, Amgen, Inc., Celgene Corporation, Pfizer, Inc., Eli Lilly and Company, UCB, Inc., Biogen Inc., and Bristol-Myers and Squibb Company.

Psoriatic Arthritis Therapeutics Market - Overview

This report by Transparency Market Research analyses the global psoriatic arthritis therapeutics market for the period between 2018 and 2026. An in-depth and unbiased market assessment has been made, which offers readers an in-depth and accurate analysis. Market projections have been offered in terms of value (US$ Mn). Stakeholders of this report include companies and intermediaries engaged in research & development, manufacture, and marketing of products prescribed in the treatment of psoriatic arthritis. 

The global psoriatic arthritis therapeutics market has been studied for the forecast period from 2018 to 2026. For research, 2017 has been considered as the base year and 2016 as the historical year. The global psoriatic arthritis therapeutics market report comprises an elaborate executive summary that provides overall information about various segments of the market. The report provides a detailed competitive landscape, by major players operating in this market along with their shares (value %) of the global psoriatic arthritis therapeutics market for 2017. The report also provides detailed company profiles of emerging market players operating in the global psoriatic arthritis therapeutics market. 

The market overview section comprises impact factors such as key market dynamics, including drivers, restraints, and opportunities, affecting the global psoriatic arthritis therapeutics market. These factors are likely to aid stakeholders establish a strong foothold in the global psoriatic arthritis therapeutics market. Furthermore, the market overview section comprises key industry events, pipeline analysis, key mergers & acquisitions across the industry, epidemiology analysis of the psoriatic arthritis, product portfolio overview of leading players, and market attractiveness analysis in the global psoriatic arthritis therapeutics market. The market attractiveness analysis provides a graphical view comparing the expansion and market dynamics in various segments and countries to identify the most attractive market. 

Scope

The global psoriatic arthritis therapeutics market has been segmented based on drug class, route of administration, distribution channel, and region. In terms of drug class, the global market has been classified into TNF inhibitors, interleukin inhibitors, PDE4 inhibitors, and others. Based on route of administration, the global market has been segregated into oral, parenteral, and topical. In terms of distribution channel, the global psoriatic arthritis therapeutics market has been categorized into hospital pharmacies, retail pharmacies, and online pharmacies. 

In terms of region, the global psoriatic arthritis therapeutics market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Moreover, quantitative analysis for major countries comprising the U.S., Canada, Germany, France, the U.K., Italy, Spain, Russia, China, Japan, India, and Australia & New Zealand has also been provided in the report. A detailed qualitative analysis of factors responsible for driving and restraining the global market in various regions has been provided in this section. 

The report provides a detailed outline/blueprint of the global psoriatic arthritis therapeutics market, which is expected to assist new companies establish their presence and companies to expand their share in the market. The report concludes with the company profiles section, which includes company overview, financial overview, SWOT analysis, product portfolio, business strategies, and recent developments of key players. 

Competitive landscape

Major players operating in the global psoriatic arthritis therapeutics market include AbbVie, Inc., Janssen Biotech, Inc., Novartis AG, Amgen, Inc., Celgene Corporation, Pfizer, Inc.,  Eli Lilly and Company, UCB, Inc., Biogen Inc., and Bristol-Myers and Squibb Company.

The global psoriatic arthritis therapeutics market has been segmented into: 

  • Global Psoriatic Arthritis Therapeutics Market, by Drug Class
    • TNF Inhibitors
    • Interleukin Inhibitors
    • PDE4 Inhibitors
    • Others
       
  • Global Psoriatic Arthritis Therapeutics Market, by Route of Administration
    • Oral
    • Parenteral
    • Topical
       
  • Global Psoriatic Arthritis Therapeutics Market, by Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
       
  • Global Psoriatic Arthritis Therapeutics Market, by Region
    • North America
      • U.S.
      • Canada
    • Europe
      • Germany
      • France
      • Italy
      • U.K.
      • Spain
      • Rest of Europe
    • Asia Pacific
      • China
      • India
      • Japan
      • Australia & New Zealand
      • Rest of Asia Pacific
    • Latin America
      • Brazil
      • Mexico
      • Rest of Latin America
    • Middle East & Africa
      • GCC Countries
      • South Africa
      • Rest of Middle East & Africa
.